Your Health, We Care
Cholangiocarcinoma: The most common adverse reactions (incidence ≥ 20%) are hyperphosphatemia, alopecia, diarrhea, nail toxicity, fatigue, dysgeusia, nausea, constipation, stomatitis, dry eye, dry mouth, decreased appetite, vomiting, arthralgia, abdominal pain, hypophosphatemia, back pain, and dry skin.
Myeloid/lymphoid neoplasms with FGFR1 rearrangement: The most common (≥ 20%) adverse reactions are hyperphosphatemia, nail toxicity, alopecia, stomatitis, diarrhea, dry eye, fatigue, rash, abdominal pain, anemia, constipation, dry mouth, epistaxis, serous retinal detachment, extremity pain, decreased appetite, dry skin, dyspepsia, back pain, nausea, blurred vision, peripheral edema, and dizziness.
from FDA，2024.06
If you experience side effects, your doctor may adjust your dose, temporarily stop, or permanently d···【more】
Recommended：332026-12-02
If you experience side effects, your doctor may adjust your dose, temporarily stop, or permanently discontinue treatment with Sepertinib. Do not change your dose or stop taking Sep···【more】
Article source：Lucius LaosRelease date：2026-02-12Recommended：33
In the medical field, each drug comes with its specific therapeutic effects and possible side effects. Serpatinib is a new type of drug, and naturally it has also attracted much at···【more】
Article source：Lucius LaosRelease date：2024-12-25Recommended：245
As an emerging drug, Selpercatinib has shown potential in the treatment of specific diseases. However, like other drugs, cerpatinib can also come with a range of side effects. The ···【more】
Article source：Lucius LaosRelease date：2024-12-25Recommended：261
Selpercatinib blocks tumor growth and spread by inhibiting the kinase activity of the RET fusion protein. As a targeted drug, it has been used to treat a variety of cancer types as···【more】
Article source：Lucius LaosRelease date：2024-08-16Recommended：243
Selpercatinib is an innovative RET inhibitor specifically designed to treat cancers associated with RET gene mutations. By interfering with the signaling pathways of cancer cells, ···【more】
Article source：Lucius LaosRelease date：2024-08-16Recommended：290
Selpercatinib is a highly selective RET inhibitor that inhibits the growth of tumor cells by blocking RET kinase activity. In May 2020, the FDA approved the drug for use as an impo···【more】
Article source：Lucius LaosRelease date：2024-08-16Recommended：230
Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp:
